Treating Alzheimer's today
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Nothing cures Alzheimer's and nothing reverses it. What exists is treatment that helps symptoms modestly, and newer treatment that slows decline somewhat in early disease.
The honest version is worth stating plainly, because the gap between what is marketed and what is delivered is unusually wide in this field.
Related pages: Memory loss and dementia (Alzheimer's)
The bottom line
- Cholinesterase inhibitors and memantine provide modest symptomatic benefit.
- Anti-amyloid antibodies remove amyloid and modestly slow decline in early disease.
- These treatments carry a risk of brain swelling and bleeding.
- Antipsychotics increase the risk of death in older people with dementia.
- How much the slowing from anti-amyloid treatment matters in daily life.
- Whether treating earlier, before symptoms, would work better.
The story, step by step
What the evidence labels mean
What they do
What happens
Two classes used for decades, with modest but real effects.
What the research shows
- Cholinesterase inhibitors, donepezil, rivastigmine and galantamine, raise levels of a signalling chemical depleted in Alzheimer's.
- They help some people modestly with memory, thinking and daily function. They do not stop the disease. Side effects are mainly stomach upset, loss of appetite, vivid dreams and a slow heart rate.
- Memantine works differently and is used in moderate to severe disease, sometimes alongside a cholinesterase inhibitor.
- Benefit varies a great deal between individuals, and a trial of a few months is the usual way to find out.
- They also help in Lewy body dementia. They are not useful in frontotemporal dementia and may worsen behaviour there.
Why it matters
These are worth trying and worth stopping if they do nothing. Modest means modest, and a family should not be told to expect more.
What's still uncertain
- Average trial effects are small, which makes individual benefit hard to judge.
Read more
- National Institute on Aging: How is Alzheimer's treated?Government
- National Institute on Aging: Alzheimer's diseaseGovernment
Next: Anti-amyloid antibodies
The new treatments
What happens
Lecanemab and donanemab, the first drugs shown to change the underlying disease.
What the research shows
- They are antibody infusions that bind amyloid and clear it from the brain, which they demonstrably do.
- In trials in early Alzheimer's they slowed decline by roughly a quarter to a third over 18 months. That is a real effect and it is a slowing, not a stopping or a reversal.
- Whether that difference is noticeable to a family is debated among clinicians, and it is a fair question to ask directly.
- Eligibility is narrow: early symptomatic Alzheimer's with confirmed amyloid, and without conditions that raise bleeding risk. Most people with established dementia are not eligible.
- They require regular infusions and repeated MRI monitoring, which is a substantial commitment.
Why it matters
These are the first treatments that act on the disease itself. They are also demanding, restricted, and not a cure.
What's still uncertain
- How much benefit accrues beyond 18 months is still being measured.
Read more
- National Institute on Aging: How is Alzheimer's treated?Government
- National Institute on Aging: Alzheimer's diseaseGovernment
Next: ARIA
The main risk
What happens
Amyloid-related imaging abnormalities, the specific risk of these drugs.
What the research shows
- ARIA means swelling or small bleeds in the brain, seen on MRI, caused by removing amyloid from blood vessel walls.
- It is often symptomless and found on routine scanning, which is why monitoring MRIs are scheduled rather than optional.
- When symptomatic it causes headache, confusion, dizziness, visual changes or seizures. Serious cases, including deaths, have occurred.
- Risk is substantially higher in people carrying two copies of APOE4, which is why genetic testing is done before starting.
- Blood thinners raise the risk of serious bleeding, and this is a specific conversation for anyone on anticoagulation.
- New headache, confusion, visual change or a seizure in someone on these drugs needs urgent assessment and a scan.
Why it matters
Anyone starting these treatments should know what ARIA is and which symptoms mean calling straight away rather than waiting.
What's still uncertain
- Long-term safety data are still accumulating.
Read more
- National Institute on Aging: How is Alzheimer's treated?Government
- OwieClear: How Alzheimer's is diagnosedOwieClear
Next: Behaviour
Treating distress
What happens
Agitation, hallucinations and distress, and the drugs often reached for.
What the research shows
- The first step is looking for a cause: pain, constipation, urinary infection, hunger, too much noise, a new medication, needing the toilet.
- Non-drug approaches work and are under-used: routine, familiar music, reduced noise and glare, activity, a calm approach, and addressing what the behaviour is communicating.
- Antipsychotic drugs carry a boxed warning about increased risk of death in older people with dementia. They are sometimes necessary for severe distress or risk, at the lowest dose for the shortest time, with regular review.
- In Lewy body dementia they can cause severe reactions and are avoided or used with great caution.
- Benzodiazepines increase falls and confusion and are generally avoided.
- Depression is common, under-treated, and worth treating in its own right.
Why it matters
A sudden behaviour change is usually a physical problem or an unmet need. Looking for that first solves more than medication does.
What's still uncertain
- Evidence for non-drug approaches is real but methodologically weaker than drug trials.
Read more
- FDA: Antipsychotic drugs and elderly patients with dementiaGovernment
- Alzheimer's AssociationNonprofit
Next: What doesn't work
Supplements and claims
What happens
An area with heavy marketing and very little evidence.
What the research shows
- No supplement has been shown to prevent or treat Alzheimer's. Ginkgo biloba, vitamin E, omega-3 and B vitamins have all been tested in trials without meaningful benefit for established disease.
- Memory supplements are a large industry and have attracted regulatory action over unsupported claims.
- Coconut oil, which circulates widely as an Alzheimer's treatment, has no supporting trial evidence.
- Treating an actual deficiency, particularly B12, is worthwhile, which is a reason to test rather than supplement blindly.
- Brain training games improve performance at the games themselves, with limited evidence of transfer to everyday function.
- Stem cell clinics and infusion treatments sold directly for Alzheimer's are not supported and are expensive.
Why it matters
If a product promises memory improvement on a shelf, it has not been shown to work. The evidence for anything in this area is in trials, not in packaging.
What's still uncertain
- Absence of benefit in trials does not entirely exclude small effects.
Read more
More plain-language reading
- OwieClear: When it's not Alzheimer'sOwieClear
- OwieClear: The core care philosophyOwieClear
- OwieClear: Reducing dementia riskOwieClear